Gastrointestinal Stromal Tumor-Background, Pathology, Treatment

Hematology/Oncology Clinics of North America

Volumn 26, Issue 6, 2012, Pages 1239-1259

  Eisenberg, Burton L ^a   Pipas, J Marc ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Gastrointestinal stromal tumor; Imatinib; KIT mutation

Indexed keywords

GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TUMOR; HUMAN; INCIDENCE; REVIEW;

GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INCIDENCE;

EID: 84868219540     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2012.08.003     Document Type: Review

References (75)

1. Perez E.A., Livingstone A.S., Franceschi D., et al. Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors. J Am Coll Surg 2006, 202:623-629.
2. Goettsch W.G., Bos S.D., Breekveldt-Postma N., et al. Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. Eur J Cancer 2005, 41:2868-2872.
3. Mucciarini C., Rossi G., Bertolini F., et al. Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study. BMC Cancer 2007, 7:230.
4. Nilsson B., Bumming P., Meis-Kindblom J.M., et al. Gastrointestinal stromal tumors: the incidence prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden. Cancer 2005, 103:821-829.
5. Tran T., Davila J.A., El Serag H.B. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol 2005, 100:162-168.
6. Hirota S., Isozaki K., Moriyama Y., et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998, 279:577-580.
7. Heinrich M.C., Corless C.L., Duensing A., et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003, 299:708-710.
8. Hirota S., Ohashi A., Nishida T., et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 2003, 125:660-667.
9. Corless C.L., Heinrich M.C. Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol 2008, 3:557-586.
10. Hohenberger P., Eisenberg B. Role of surgery combined with Kinase inhibition in the management of Gastrointestinal Stromal Tumor (GIST). Ann Surg Oncol 2010, 17:2585-2600.
11. Casali P.G., Jost L., Reichardt P., et al. Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009, 20(Suppl 4):64-67.
12. Kawanowa K., Sakuma Y., Sakurai S., et al. High incidence of microscopic gastrointestinal stromal tumors in the stomach. Hum Pathol 2006, 37:1527-1535.
13. Agaimy A., Wunsch P.H., Hofstaedter F., et al. Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol 2007, 31(1):113-120.
14. Corless C.L., McGreevey L., Haley A., et al. C-Kit mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 2002, 160:1567-1572.
15. Corless C.L., Barnett C., Heinrich M. Gastrointestinal stromal tumors: origin and molecular oncology. Nat Rev Cancer 2011, 11:865-878.
16. Choi H. Response evaluation of gastrointestinal stromal tumors. Oncologist 2008, 13(2):4-7.
17. Miettinen M., Sobin L.H., Sarlomo-Rikala M. Immunohistochemical spectrum of GIST's at different sites and their differential diagnosis with a reference to CD117 (KIT). Mod Pathol 2000, 13:1134-1142.
18. Lasota J., Dansonka-Mieszkowska A., Sobin L., et al. A great majority of GIST's with PDGFRA mutations represents gastric tumors of low or no malignant potential. Lab Invest 2004, 84:874-883.
19. Wardelmann E., Buttner R., Merkelback-Bruse S., et al. Mutation analysis of gastrointestinal stromal tumors: increasing significance for risk assessment and effective targeted therapy. Virchows Arch 2007, 451:743-749.
20. Mol C.D., Dougan D.R., Schneider T.R., et al. Structural basis for the autoinhitibion and STI-571 inhibition of c-kit tyrosine kinase. J Biol Chem 2004, 279:31655-31663.
21. Wardelmann E., Losen I., Hans V., et al. Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors. Int J Cancer 2003, 106:887-895.
22. Heinrich M., Corless C.L., Demetri G.D., et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003, 21:4342-4349.
23. Gajiwala K., Wu J.C., Christensen J., et al. KIT kinase mutants show unique mechanisms of drug resistence to imatinib and sunitinib in gastrointestinal tumors. Proc Natl Acad Sci U S A 2009, 106:1542-1547.
24. Heinrich M., Maki R.G., Corless C.L., et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib resistant gastrointestinal stromal tumor. Clin Oncol 2008, 26:5352-5359.
25. Fletcher C.D., Berman J.J., Corless C., et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002, 33(5):459-465.
26. Singer S., Rubin B.P., Lux M.L., et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol 2002, 20:3898-3905.
27. Emory T.S., Sobin L.H., Lukes L., et al. Prognosis of gastrointestinal stromal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol 1999, 23:82-87.
28. Miettinen M., Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006, 23:70-83.
29. Takahashi T., Nakajima K., Nishitani A., et al. An enhanced risk-group stratification system for more practical prognostication of clinically malignant gastrointestinal stromal tumors. Int J Clin Oncol 2007, 12:369-374.
30. Gold J.S., Gonen M., Gutierez A., et al. Development and validation of a prognostic nomogram for recurrence free survival after complete surgical resection of localized primary gastrointestinal stromal tumor: a retrospective analysis. Lancet Oncol 2009, 10:1045-1052.
31. Ng E.H., Pollock E., Munssell M.F., et al. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg 1992, 215:68-77.
32. DeMatteo R.P. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000, 231:51-58.
33. Pierie J.P., Choudry U., Muzikanski A., et al. The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg 2001, 136:383-389.
34. Roberts P., Eisenberg B. Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease. Eur J Cancer 2002, 38:S37-S38.
35. Hindmarsh A., Koo B., Lewis M.P., et al. Laparoscopic resection of gastric gastrointestinal stromal tumors. Surg Endosc 2005, 19:1109-1112.
36. Choi Sm, Kim M.C., Jung G.J., et al. Laporscopic wedge resection for gastric GIST: long term follow-up results. Eur J Surg Oncol 2007, 33:444-447.
37. NCCN (version 1.2009) The NCCN soft tissue sarcoma clinical practice guidelines in oncology. © National Comprehensive Cancer Network, Inc. Hollywood (FL) 2009, 1(15).
38. Demetri G.D., von Mehren M., Blanke C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002, 347:472-480.
39. Blanke C.D., Rankin C., Demetri G.D., et al. Phase III randomized intergroup trial assessing imatinib meslyate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the Kit receptor tyrosine kinase. S0033. J Clin Oncol 2008, 26:626-632.
40. von Mehren M. Follow-up results after 9 years of the on-going phase II B2222 trial of imatinib mesylate in patients with metastatic or unresectable KIT positive gastrointestinal stromal tumors. J Clin Oncol 2011, 29. [abstract 10016].
41. Nilsson B., Sjolund K., Kindblom L.G., et al. Adjuvant imatinib treatment improves recurrence-free survival in patients with high risk gastrointestinal stromal tumors. Br J Cancer 2007, 96:1656-1658.
42. Brumming P., Andersson J., Meis-Kindblom J.M., et al. Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumors with imatinib: a center based study of 17 patients. Br J Cancer 2003, 89:460-464.
43. Dematteo RP, Owzar K, Antonescu C, et al. Efficacy of adjuvant imatinib mesylate following complete resection of localized primary GIST at high risk of recurrence [abstract 8]. ASCO 2008 Gastrointestinal Cancers Symposium, Chicago (IL). 2008.
44. Dematteo R.P., Ballman K.V., Antonescu C.R., et al. Adjuvant imatinib meslyate after resection of localized primary gastrointestinal stromal tumor: a randomized, double-blind, placebo-controlled trial. Lancet 2009, 373:1097-1104.
45. Corless C.L., Ballman K.V., Antonescu C., et al. Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary GIST. Results of the intergroup phase III trial ASOSOG Z9001. J Clin Oncol 2010, 28:10006. [abstracts].
46. Joensuu H., Eriksson M., Sundby Hall K., et al. One vs. three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 2012, 307(12):1265-1272.
47. Eisenberg B., Smith K. Adjuvant and neoadjuvant therapy for primary GIST. Cancer Chemother Pharmacol 2011, 67:S3-S8.
48. Eisenberg B., Judson I. Surgery and imatinib in the management of GIST. Emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol 2004, 5:465-475.
49. Andtbacka R., Ng D.S., Scaife C.L., et al. Surgical resection of gastrointestinal stromal tumor after treatment with imatinib. Ann Surg Oncol 2007, 14:14-24.
50. Raut C., Posner M., Desai J., et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006, 24:2325-2331.
51. Blesius A., Cassier P.A., Bertucci F., et al. Neoadjuvant imatinib in patients with locally advanced non-metastatic GIST in the prospective BFR14 trial. BMC Cancer 2011, 11:72-79.
52. Eisenberg B., Harris J., Blanke C.D., et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary, metastatic/recurrent operable GIST-early results of RTOG 0132. J Surg Oncol 2009, 99:42-47.
53. Wang D., Zhang Q., Blanke C.D., et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long term follow-up results of Radiation Therapy Oncology Group 0132. Ann Surg Oncol 2012, 19(4):1074-1080.
54. Bauer S., Hartmann J.T., de Wit M., et al. Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int J Cancer 2005, 117:316-325.
55. Ryan D.P., Puchalski T., Supko J.G., et al. A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors. Oncologist 2002, 7:531-538.
56. Edmonson J.H., Marks R.S., Buckner J.C., et al. Contrast of response to dacarbazine, metomycin, docorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomuyosarcomas. Cancer Invest 2002, 20:605-612.
57. Heinrich M.C., Griffith D.J., Druker B.J., et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000, 96:925-932.
58. Tuveson D.A., Willis N.A., Jacks T., et al. STI 571 inactivation of the gastrointestinal stromal tumor c-Kit oncoprotein: biological and clinical implications. Oncogene 2001, 20:5054-5058.
59. Druker B.J., Tamura S., Buchdunger E., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996, 2(5):561-566.
60. Buchdunger E., Cioffi C.L., Law N. Abl protein tyrosine kinase inhibitor STI 571inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000, 295:139-145.
61. Joensuu H., Roberts P.J., Sarlomo-Rikala M., et al. Effect of the tyrosine kinase inhibitor ST1571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001, 344:1052-1056.
62. van Oosterom A.T., Judson I., Verweij J., et al. Safety and efficacy of imatinib (ST1571) in metastatic gastrointestinal stromal tumors: a phase I study. Lancet 2001, 358:1421-1423.
63. Verweij J., Casali P.G., Zalcberg J., et al. Progression-free survival in gastrointestintal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004, 364:1127-1134.
64. Casali P., Verweij J., Kotasek D. Imatinib mesylate in advanced gastrointestinal stromal tumors (GIST): survival analysis of the EORTC ISG AGITG randomized trial in 946 patients. Eur J Cancer Suppl 2005, 2:201. [abstract 711].
65. Le Cesne A., Ray-Coquard I., Bui B.N., et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicenter randomized phase 3 trial. Lancet Oncol 2010, 11(10):942-949.
66. Van den Abbeele A.D., Badawi R.D., Manola J., et al. Effects of cessation of imatinib mesylate (IM) therapy in patients with IM refractory gastrointestinal stromal tumors as visualized by FDG-PET scanning. J Clin Oncol 2004, 22(Suppl 14). [abstract 3012].
67. Choi H., Charnsangavej C., de Castro Faria S., et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol 2004, 183:1619-1628.
68. Benjamin R.S., Choi H., Macapinlac H.A., et al. We should desist using RECIST, at least in GIST. J Clin Oncol 2007, 25:1760-1764.
69. Choi H., Charnsangavej C., Faria S.C., et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007, 25(13):1753-1759.
70. Shankar S., vanSoonenberg E., Desai J., et al. Gastrointestinal stromal tumor: new nodule within a mass pattern of recurrence after partial response to imatinib mesylate. Radiology 2005, 235:892-898.
71. Demetri G., van Oosterom A.T., Garrett C.R., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomized controlled trial. Lancet 2006, 368:1329-1338.
72. Kindler H. Sorafenib in patients with imatinib and sunitinib resistant gastrointestinal stromal tumor: final results of a University of Chicago phase II consortium trial. J Clin Oncol 2011, 29(Suppl). [abstract 10009].
73. Nishida T., Sawaki A., Doi T. Phase II trial of nilotinib as third-line therapy for gastrointestinal stromal tumor (GIST) patients in Japan. J Clin Oncol 2010, 15(Suppl). [abstract 10015].
74. Trent J.C. A phase II study of dasatinib for patients with imatinib resistant gastrointestinal stromal tumor. J Clin Oncol 2011, 29(Suppl). [abstract 10006].
75. George S. A multicenter phase II study of regorafenib in patients with advanced gastrointestinal stromal tumor, after therapy with imatinib and sunitinib. J Clin Oncol 2011, 29(Suppl). [abstract 10007].